Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults …
G Moeck, LB Gasink, RE Mendes… - Antimicrobial Agents …, 2024 - Am Soc Microbiol
ABSTRACT CERTAIN-1 was a Phase 3, double-blind, randomized, parallel group study of
the efficacy and safety of cefepime-taniborbactam versus meropenem in the treatment of …
the efficacy and safety of cefepime-taniborbactam versus meropenem in the treatment of …
Evaluation of Factors Predictive of Efficacy Among Patients With Complicated Urinary Tract Infection and/or Acute Pyelonephritis
SM Bhavnani, JP Hammel, CM Rubino… - Open Forum …, 2024 - academic.oup.com
Background Antibiotic treatment for complicated urinary tract infections (cUTI)/acute
pyelonephritis (AP) is often followed by recurrent bacteriuria in the absence of clinical …
pyelonephritis (AP) is often followed by recurrent bacteriuria in the absence of clinical …
Antibacterial prodrugs
R Žalubovskis - Advances in Prodrugs, 2025 - Elsevier
Bacterial resistance against antibiotics is a growing threat to the society. Various
approaches are used for the development of new resistance-free antibiotics. As an important …
approaches are used for the development of new resistance-free antibiotics. As an important …
[PDF][PDF] MAJOR ARTICLE
M Sujata, JP Hammel, CM Rubino, AK Talley… - 2024 - oxfordjournals.org
Background: Antibiotic treatment for complicated urinary tract infections (cUTI)/acute
pyelonephritis (AP) is often followed by recurrent bacteriuria in the absence of clinical …
pyelonephritis (AP) is often followed by recurrent bacteriuria in the absence of clinical …